Invention Grant
- Patent Title: Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
-
Application No.: US14396771Application Date: 2013-04-24
-
Publication No.: US09688695B2Publication Date: 2017-06-27
- Inventor: Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
- Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agency: Hoffmann & Baron, LLP
- International Application: PCT/US2013/037956 WO 20130424
- International Announcement: WO2013/163279 WO 20131031
- Main IPC: C07D513/04
- IPC: C07D513/04 ; C07D487/04 ; C07D519/00 ; A61K45/06 ; A61K31/433 ; A61K31/4439 ; A61K31/454 ; A61K31/496 ; A61K31/497 ; A61K31/5025 ; A61K31/5377 ; A61K31/541 ; A61K31/553

Abstract:
The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Public/Granted literature
Information query